Group 1 - The core focus of the news is the initiation of a Phase I clinical trial for Wanbangde Pharmaceutical Group's oral solution and injection of Huperzine A, aimed at comparing their pharmacokinetic characteristics in healthy Chinese subjects [1] - The clinical trial is designed as a single-center, randomized, open-label, single-dose, two-period, two-sequence, crossover study, with a registration number of CTR20255231 and the first public information date set for December 30, 2025 [1] - The primary objective of the trial is to compare the pharmacokinetic profiles of the oral solution and injection of Huperzine A under fasting conditions, while secondary objectives include assessing the relative bioavailability of the oral solution and the safety of both formulations [1] Group 2 - The main endpoints of the trial include pharmacokinetic parameters such as Cmax, AUC0-t, and AUC0-∞, while secondary endpoints include Tmax, λz, t1/2, AUC_%Extrap, CL/F, Vz/F, relative bioavailability F, physical examinations, vital signs, 12-lead ECG, laboratory tests, and adverse events [2] - The current status of the trial is ongoing, with a target enrollment of 20 participants, although recruitment has not yet started [2]

Core Viewpoint - Wanbangde's subsidiary has received ethical approval for the Phase I clinical trial of WP107, a new drug for treating myasthenia gravis, indicating progress in its drug development pipeline [1] Group 1: Clinical Trial Developments - Wanbangde's subsidiary, Wanbangde Pharmaceutical Group, has obtained approval from the ethics committee of Wenzhou Medical University for the Phase I clinical trial of WP107 [1] - The trial aims to compare the pharmacokinetic characteristics of oral and injectable forms of huperzine A in healthy Chinese subjects under fasting conditions [1] - The company received orphan drug designation from the FDA for huperzine A in December 2023, and has been granted clinical trial approval for WP107 in January 2025 [1] Group 2: Regulatory Approvals - The FDA granted clinical trial permission for WP107 in January 2025, with further approval from the National Medical Products Administration for a Class 2 new drug trial in July 2025 [1] - The ethical approval is a significant step in the drug development process, allowing the company to officially commence the Phase I clinical trial [1]

Core Viewpoint - Wanbangde (002082.SZ) has received approval from the medical ethics committee of Wenzhou Medical University for its Phase I clinical trial of the new drug WP107, aimed at treating myasthenia gravis [1] Group 1: Clinical Trial Progress - The company’s wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has officially commenced the Phase I clinical trial after obtaining the clinical trial approval notice from the National Medical Products Administration [1] - The trial will compare the pharmacokinetic characteristics of oral and injectable forms of Huperzine A in healthy Chinese subjects under fasting conditions [1] - The objective is to evaluate the relative bioavailability of the oral solution of Huperzine A and the safety of both formulations in a fasting state [1]